| First Author | Winkler R | Year | 2022 |
| Journal | Cells | Volume | 12 |
| Issue | 1 | PubMed ID | 36611833 |
| Mgi Jnum | J:332506 | Mgi Id | MGI:7426265 |
| Doi | 10.3390/cells12010037 | Citation | Winkler R, et al. (2022) Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma. Cells 12(1) |
| abstractText | Oncogenic overexpression of MYC leads to the fatal deregulation of signaling pathways, cellular metabolism, and cell growth. MYC rearrangements are found frequently among non-Hodgkin B-cell lymphomas enforcing MYC overexpression. Genetically engineered mouse models (GEMMs) were developed to understand MYC-induced B-cell lymphomagenesis. Here, we highlight the advantages of using Emicro-Myc transgenic mice. We thoroughly compiled the available literature to discuss common challenges when using such mouse models. Furthermore, we give an overview of pathways affected by MYC based on knowledge gained from the use of GEMMs. We identified top regulators of MYC-induced lymphomagenesis, including some candidates that are not pharmacologically targeted yet. |
